ECG timing
Protocols may collect a baseline ECG and repeat ECGs across the period when ibogaine and noribogaine are considered relevant. Published timing is not uniform.
Evidence & safety review
Cardiac Safety Profile
A technical-but-readable review of the published cardiac safety signal around ibogaine and noribogaine: pharmacology, reported QTc effects, arrhythmia context, monitoring practices, and what remains unknown.
Informational review — not medical advice
How to read this page
Separate the kinds of evidence.
Cardiac risk discussions can blur laboratory mechanisms, clinical observations, and case reports into one claim. This page keeps those evidence types distinct. For a broader map of the questions considered across the site, the Infinigaine research overview sets out the wider evidence, safety, legality, and practical context.
Published case reports can document serious events and potential contributing circumstances, but commonly cannot determine causation on their own. Observational reports can describe ECG changes in defined groups, while remaining vulnerable to selection, co-exposures, and incomplete follow-up. Preclinical findings can identify plausible mechanisms, but do not convert directly into a person-specific prediction.
QTc refers to a heart-rate-corrected interval on an electrocardiogram. The general relationship between delayed ventricular repolarisation, QT prolongation, and torsades de pointes is described by the FDA’s drug-induced arrhythmia safety information. That general framework is useful here, but it does not establish a safe dose or safe setting for ibogaine.
- MechanismCell and receptor studies identify a plausible pathway for QT-related concern.
- ContextReports often involve substance use history, vomiting, electrolyte disturbance, or other medicines.
- UncertaintyHeterogeneous records limit clean comparisons across reported events.
Pharmacology & timing
Why ibogaine and noribogaine both matter.
Ibogaine is metabolised in part to noribogaine. The parent compound and metabolite have different time courses, so a narrow focus on an initial exposure can miss the longer pharmacokinetic window discussed in safety literature. Variation in metabolism, co-administered substances, and hepatic function can complicate attempts to infer an individual exposure from a reported amount alone.
A leading proposed mechanism for QTc prolongation is inhibition of the cardiac hERG potassium channel, part of the IKr current that contributes to ventricular repolarisation. The hERG channel reference overview explains why channel blockade is a recurring concern in drug-induced QT discussions. This is mechanistic evidence: it supports biological plausibility, not a complete account of every event reported in people.
Interpretive point
Pharmacokinetics relevant to cardiotoxicity include persistence of active compounds, delayed peak effects, metabolic variability, and interaction potential. Published literature does not support reducing this to one universal observation window.
Reported cardiac events
What the reports can — and cannot — show.
Peer-reviewed reports describe QTc prolongation, ventricular arrhythmia, and deaths in settings where ibogaine exposure was reported or confirmed. Their clinical context is essential: many records include incomplete dose data, concomitant drugs, recent substance use, or physiological stressors. The table summarises recurring report patterns rather than estimating incidence.
| Evidence type | Dose / exposure context | Concomitant factors described | Reported outcome |
|---|---|---|---|
| Case reports | Reported oral ibogaine exposure; dose documentation varies and may be incomplete. | Some accounts describe recent substance use, medicines with cardiac relevance, vomiting, or possible electrolyte disruption. | Marked QTc prolongation and, in severe reports, polymorphic ventricular arrhythmia or death. |
| Observational ECG series | Structured or semi-structured settings with serial ECG assessment in some cohorts. | Participant selection and screening differ across reports; full interaction histories are not always available. | QTc prolongation commonly described; most reports do not establish a population incidence of rare arrhythmia. |
| Preclinical studies | In vitro or animal exposure designs; not equivalent to clinical dose comparison. | Controlled experimental conditions rather than real-world polysubstance context. | Findings consistent with repolarisation-related mechanisms, including ion-channel effects. |
QTc prolongation is a signal, not a diagnosis.
QTc values depend on ECG method, correction formula, heart rate, timing, and interpretation. In the published ibogaine record, serial changes and accompanying circumstances are generally more informative than treating any one number as self-explanatory.
Concomitant drugs can change the picture.
Drug-interaction screening is relevant because other substances may independently prolong QT, alter electrolyte balance, or affect metabolic pathways. A reported co-exposure does not prove that it caused an event, but it can prevent a clean attribution to one compound.
Clinical records are often incomplete.
Case literature may not include verified dosing, baseline ECGs, serial electrolytes, toxicology, or a complete medication history. Those gaps matter when attempting to compare events or infer a mechanism.
Fatal reports are not incidence studies.
A case report identifies a serious occurrence; it cannot provide a denominator for frequency. Conversely, a small observational cohort without an event cannot exclude rare but severe outcomes.
Monitoring in research settings
What published protocols try to observe.
Research and medically supervised reports have commonly described baseline and follow-up ECG assessment, electrolyte checks, and medication or substance interaction review. These are descriptions of monitoring strategies used in published contexts, not instructions for self-management or a substitute for individual clinical judgement. The National Heart, Lung, and Blood Institute’s arrhythmia overview provides general background on rhythm disorders and why symptoms alone are not a complete assessment.
Electrolyte context
Potassium, magnesium, and other physiological factors can matter in QT-related risk discussions, especially where vomiting, dehydration, or other stressors are documented.
Interaction review
Reports commonly treat prescribed medicines, non-prescribed substances, and recent exposures as variables that need to be documented rather than assumed away.
Outstanding evidence gaps
The most important answers are still incomplete.
There is no robust, broadly generalisable evidence base that can predict which person will experience clinically significant arrhythmia after ibogaine exposure. Better studies would need transparent inclusion criteria, verified exposure data, serial ECG methods, interaction documentation, electrolyte data, and follow-up adequate to capture delayed changes.
The site’s research gaps and protocol guide examines the methodological questions behind those missing data. For readers comparing the scope and limits of an independent resource, the principles behind Infinigaine’s approach explain the emphasis on plain language and evidence boundaries.
What does QTc prolongation mean in this context?
QTc is a heart-rate-corrected ECG measure of ventricular repolarisation. In ibogaine literature, prolongation is treated as a safety signal because excessive delay in repolarisation can be associated with torsades de pointes in susceptible circumstances.
Do published reports establish a predictable dose-response relationship?
No. Published reports are heterogeneous and often lack complete dose confirmation, serial ECG data, toxicology, electrolyte values, or medication histories. They do not establish a reliable threshold or individual prediction rule.
Why distinguish ibogaine from noribogaine?
Ibogaine is metabolised to noribogaine, which can persist longer. Both compounds are relevant when considering timing, interaction uncertainty, and the length of observation described in research settings.
Where does this fit in depression-related research?
Cardiac safety concerns remain relevant regardless of the reason a person is researching ibogaine. People reviewing ibogaine treatment for depression should keep efficacy questions separate from the distinct question of cardiac safety evidence.
Evidence, in context
Continue with the broader evidence summary.
This cardiac profile is one part of a larger review for people researching ibogaine. It does not offer treatment, screening, or legal advice.